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Induction docetaxel and cisplatin followed of bi-weekly docetaxel 
with concurrent thoracic radiotherapy for stage III non-small cell 
lung cancer (NSCLC). A phase II study conducted by the Galician 
Lung Cancer Group (GLCG).
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Background: The most satisfactory treatment for patients with locally 
advanced NSCLC is combination chemotherapy-radiotherapy (CT-RT). 
The optimal treatment modalities remain to be determined.
Methods: 60 patients (pts) with inoperable locally advanced NSCLC, 
stage IIIAN2/IIIB (no pleural T4), were included in a phase II study 
with induction chemotherapy consisting of three cycles of Docetaxel 
75 mg/m2 on D1 and Cisplatin 40 mg/m2 D1-2 every 3 weeks and, if 
no surgery, then received concurrent CT-RT with Docetaxel 30 mg/m2 
every 2 weeks for four courses, during thoracic conformal radiotherapy 
(60-66 Gys, 180 cGy/day). The primary objective: overall survival; 
secondary: progression free survival, response rate (RR) and toxicity. 
Median follow-up: 9.1 mo.
Results: The pts characteristics were: mean age 62.9 yrs (43-74); male/
female: 56/4; ECOG 0/1 in 17/43 pts; stage IIIAN2: 17 pts (28.3%) and 
stage IIIB 43 pts (71.7%). 56 pts were evaluables for response and 58 
pts for toxicity. Induction chemotherapy response: 1 CR and 34 PR (RR 
62.5%; CI95%:50-75), 16 SD (28.6%) and 5 PD (8.9%). 6 pts went to 
surgery: 3 pPR, 1 pSD, 1 pPD and 1 unresectable. 34 pts completed 
concurrent CT-RT treatment with 6 CR, 21 PR, 4 SD and 3 PD (RR 
79.3%; CI95%:66-93). The median time to progression was 13 mo and 
median overall survival was 14 mo. The progression-free survival and 
overall survival at 1 year was 52% and 62% respectively. A total of 
163 cycles of induction chemotherapy were administered (2.8 per pts), 
with the main toxicity (NCI-CTC) per pts Grade (g) 1-2/3-4 (%) was 
as follows: neutropenia 20.6/24.1; anemia 44.8/1.7; nausea/vomiting 
39.6/1.7; fatigue 34.5/1.7; diarrhea 22.4/0; allergy 5.2/1.7; one toxic 
death were scored. The main toxicities (RTOG) in concurrent CT-RT 
were: g1-2 neutropenia/anemia 30.7/38.4 5% of pts; g1-2/3 esophagitis 
in 51.2/2.5% and g1-2/3 pneumonitis in 20.5/2.5 % of pts.
Conclusions: Docetaxel and Cisplatin induction chemotherapy fol-
lowed by bi-weekly docetaxel with concurrent thoracic radiotherapy 
is a feasible treatment option, showing good clinical activity and toler-
ability for locally advanced NSCLC.
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Is 2D versus 3D planning detrimental for local control and survival 
in preoeperative radiochemotherapy in NSCLC?
Casas, Francesc1 Viñolas, Núria2 Gimferrer, Josep Maria2 Ferrer, 
Ferran3 Carcereny, Enric2 Marrades, Ramon4 Sanchez, Marcelo4 
Lomeña, Francisco4 Marruecos, Jordi4 
1 Radiation Oncology Departament, Lung Cancer Committee, Barce-
lona, Spain 2 Lung Cancer Committee, Barcelona, Spain 3 Radiation 
Oncology Dept. ICO, Barcelona, Spain 4 Lung Cancer Committee 
Hosp. Clinic, Barcelona, Spain 
Background: We carried out a phase II trial to evaluate a regimen of 
polychemotherapy delivered concurrently with accelerated modiﬁed 
hyperfracctionated radiotherapy (AMHR) in NSCLC stage III patients. 
A subanalysis was made of the impact of planning method (2D versus 
3D) on local control and overall survival.
Methods: Thirty eight patients (pts) received neoadjuvant therapy 
consisting of AMHR 40.2 Gy over 3 weeks (1,8 +0,88 Gy, by concomi-
tant boost), concurrent with the second cycle of chemotherapy using 
cisplatin 80 ml/m2 on day 1, ifosfamide 1.5 gr/m2 on day 1 and VP-16 
100 mg/m2 for 3 days. 
Results: From October 1997 to October 2002, 38 pts were treated. 
The most frequent cell type was squamous cell carcinoma, 20 (54%), 
and adenocarcinoma 11, (30%). From 1997 to June 1999, 17 pts were 
prepared with 2D. After this date 21 pts were done with 3D. Clinical 
response to CRT at restaging was observed in 30 pts (79%). One pt 
(3%) had complete response, 16 pts (42%) partial response, 13 (34%) 
stable disease and 4 pts (8%) developed progression. Surgery included 
pneumonectomy (n=14), bilobectomy (n=1) and lobectomy (n=14) and 
exploratory thoracotomy (n=1). Pathologic examination of the resected 
tissue demonstrated no residual viable tumor, (pathologic CR) in 13 / 
28 completely resected pts (45%). Clinical response of pts with pCR 
when evaluated before surgery was partial in 8, stable disease in 4 and 
complete response in one. Overall 20 (69%) pts had sterilization of 
mediastinal lymph nodes and downstaging .There was 1 surgically-re-
lated death. Maximum toxicity was: esophagitis grade II in 8 pts (22%) 
and III in 1 pt (3%), neutropenia grade III -IV in 24%, thrombocyto-
penia grade III-IV in 13% and anemia grade III-IV in 10.5%. Twelve 
pts (32%) required hospitalisation due to toxicity. Stratiﬁed by type of 
planning disease free survival differed with more local control in the 
2D arm ( 16 months for 2D versus 11.91months with 3D) but without 
statistical signiﬁcance. Overall survival was also equivalent.
Median survival for the whole series was 22 months with survival at 5 
years being 21.38 %. Median and 5 - year survival for patients who did 
or did not undergo surgery were 26.5 months, 35% and 8 months and 
0%, respectively .
Conclusions: In this neoadjuvant radiochemotherapy treatment the 
type of planning ( 2D versus 3D) is not signiﬁcantly detrimental on 
local control or overall survival although a trend to lesser local control 
has been detected in pts prepared for 3D. This trend may be due to 
the learning curve and a lack of planning norms such as published by 
Senan et al in 2004.
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Purpose: To evaluate the efﬁcacy, toxicity and compliance associated 
with adjuvant Carboplatin and Gemcitabine (CBDCA - GEM) admin-
istration in completely resected patients with stage I - IIIA non-small 
lung cancer (NSCLC) 
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Patient and Methods: Twenty-four patients with completely resected 
stage I-IIIA non-small lung cancer were administered 3 cycles of 
adjuvant chemotherapy consisting of carboplatin at an AUC of 4 and 
gemcitabine at dose 1000mg/m2 on day 1 and 15, in a 4-week cycle. 
Patients’ average age was 56.5 years and 96% of patients had ECOG 
performance status 0; 41.6% had pathological stage IIIA and 58.4% 
stage IB and II. Histologic tumor subtype was: 62.5% adenocarcinoma, 
33.3% squamous cell carcinoma and 4.1% large-cell undifferentiated 
carcinoma.
Results: All patients enrolled in the study received the planned 3 
cycles of adjuvant chemotherapy (compliance 100%). Myelotoxicity 
of all grades was observed in 8(33.3%) patients; grade 1-2 anemia in 
7(29%), grade 1-3 thrombocytopenia in 2(8.3%) and grade 1 leucope-
nia in 1(4.1%). G-CSF at dose 33.6miu/day s.b. was administered on 
D4-D6 and D18-D20 of each cycle. Non-hematologic toxicity consist-
ed of all grade nausea/vomiting(12.5%) and all grade diarrhea(8.3%). 
No treatment-related death was observed. The 2-year survival rate was 
87.5%, and especially for stage IIIA patients 70%. A 5-year follow-up 
is ongoing.
Conclusions: We identiﬁed a comparable efﬁcacy of adjuvant 
Carboplatin+Gemcitabine combination regimen with the one observed 
with Cisplatin-based chemotherapy regimens, however exhibiting a 
better toxicity proﬁle and a high standard of compliance. 
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Twice a day radiation therapy concomitant chemotherapy in 
locally advanced non small cell lung cancer
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Background: Combination of chemotherapy and thoracic radiation 
therapy is the best available treatment for locally advanced unresect-
able NSCLC. Results of conventional RT and CT are still not up to the 
acceptable level. We conducted a trial to compare chemotherapy given 
concurrently with twice daily external radiotherapy and conventional 
external radiotherapy alone in locally advanced NSCLC.
Methods: Fifty patients of locally advanced unresectable NSCLC were 
inducted into two arms, A & B. Twenty ﬁve patients of arm-A received 
chemotherapy with Cisplatin 75mg/m2 intravenously given starting on 
day 1 of radiation therapy for 5 courses at 3 weeks interval and vinblas-
tine 5mg/m2 given weekly for 5 courses starting on day 1 of radiation 
along with twice daily external thoracic radiation therapy. The radiation 
was given twice daily at a dose of 1.3 Gy per fraction with each frac-
tion separated by a minimum of 6 hours. A total dose of 60 Gy in 46 
fractions over 4 weeks and 3 days was delivered. Twenty ﬁve patients 
of arm-B received only conventional external radiotherapy 60Gy in 30 
fractions, 5 days a week over 6 weeks.
Results: Six weeks after the completion of treatment 67% of the 
patients in arm A showed some tumor response (27% CR; 40% PR) as 
compared to only 42% patients in the arm B. The only severe toxici-
ties observed were leucopenia (5 patients in arm A) and esophagitis, 
grade 3 (4 patients in the arm A and 3 patients in arm B). At one year 
the survival rates were 61% in arm A and 39% in the arm B. No patient 
required hospitalization due to treatment related toxicity.
Conclusion: To conclude, hyper fractionated radiotherapy and che-
motherapy regimen has promising efﬁcacy and manageable toxicity in 
unresectable advanced NSCLC.
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Phase II and pharmacokinetic (PK) study of induction docetaxel/
cisplatin followed by pulsed docetaxel chemoradiation for stage III 
non-small cell lung cancer
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Background: Both local and distant failure rates are high for inoper-
able NSCLC treated by combination chemoradiation (CRT). We have 
previously reported that docetaxel (Doc) demonstrates longer G2/M 
arrest and better sub-additive effects with radiation when compared 
with paclitaxel in pre-clinical investigations. We subsequently reported 
a clinical study using pulsed low-dose paclitaxel radiosensitizing 
strategy, which yielded a 98% in-ﬁled chest tumor control rate [Clin 
Cancer Res, 9: 969-975, 2003]. With the encouraging local tumor con-
trol by pulsed taxane CRT, we conducted a phase II study using pulsed 
low-dose sensitizing Doc CRT targeting local tumor, plus one-cycle of 
induction chemotherapy (CT) of Doc/cisplatin (CP) targeting distant 
micrometastasis upfront for patients (pts) with stage III NSCLC.
Methods: Pts with inoperable stage III NSCLC were eligible. Induc-
tion CT consisted of Doc 75mg/m2 and CP 75mg/m2 on d 1 followed 
by rhG-CSF (150 ug/m2 sq on d 2 to 10). The CRT consisted of Doc 12 
mg/m2 twice/wk with daily RT, 64.8 Gy to gross tumors and 45-57.6 
Gy to subclinical disease. PK studies of Doc were performed during CT 
and during CRT in each pt. The clearance (CL), area under the plasma 
concentration versus time curve (AUC), and drug half-life (t1/2) were 
estimated.
Results: 26 pts were enrolled and 16 completed study. Overall response 
rate was 69% [50% (8/16) PR and19% (3/16) CR]. 2-year survival was 
57 %. During induction CT, primary grade (G) 3 toxicities were allergic 
reaction (10%), non-neutropenic infection (20%), nausea/vomiting 
(N/V) (10%), fatigue (10%), hypertension (5%) hyperglycemia (5%), 
dyspnea (5%) & fatigue (5%). There was no G3/4 hematologic toxicity. 
During CRT, 50% (4/8) developed grade 3 esophagitis at the initial 
twice-weekly Doc dose of 12 mg/m2. Eight subsequent pts received 
reduced Doc to 10 mg/m2 with only one grade 3 esophagitis. Other G3 
toxicities from CRT were N/V(28%), fatigue(14%), anorexia(14%), 
ﬂushing(7%), chest pain(7%), & diarrhea(7%). We observed no G3 or 4 
pneumonitis or any other G4 toxicity. Mean ± SD of Doc CL at 75 and 
10 mg/m2 was 20 ± 5 and 22 ± 10 L/h/m2, respectively. Ratio of Doc 
CL at 75 to 10 mg/m2 within a pt was 1.0 ± 0.4. Doc AUC at 75 and 10 
mg/m2 was 3,933 ± 1,028 and 566 ± 257ng/ml•h, respectively, with a 
ratio of 8.31 ± 3.84 for 75 mg/m2 to 10 mg/m2. Half-life of Doc at 75 
and 10 mg/m2 was 15.4 ± 3.7 hrs and 15.0 ± 2.2 hrs, respectively, with 
a ratio of 1.08 ± 0.15. 
Conclusions: One-cycle full-dose Doc/CP with rhG-CSF followed 
by pulsed low-dose Doc CRT is associated with promising antitumor 
activity and low hematologic toxicity. Grade 3 esophagitis was associ-
